Filter Results:
(1,161)
Show Results For
- All HBS Web
(1,161)
- People (5)
- News (420)
- Research (590)
- Multimedia (6)
- Faculty Publications (123)
Show Results For
- All HBS Web
(1,161)
- People (5)
- News (420)
- Research (590)
- Multimedia (6)
- Faculty Publications (123)
- 08 May 2022
- Blog Post
The Territory of Motherhood: A Reflection in Honor of Mother’s Day
have spent twenty days in the NICU watching our babies become strong enough to come home. All of our first interactions have been tangled with cords and closely watched by wonderful nurses as we grew the confidence to care for our tiny... View Details
- August 2016
- Article
Value-Based Breast Cancer Care: A Multidisciplinary Approach for Defining Patient-Centered Outcomes
By: Fayanju M. Oluwadamilola, Tinisha L. Mayo, Tracy E. Spinks, Seohyun Lee, Carlos H. Barcenas, Benjamin D. Smith, Sharon H. Giordano, Rosa F. Hwang, Richard A. Ehlers, Jesse C. Selber, Ronald Walters, Debu Tripathy, Kelly K. Hunt, Thomas A. Buchholz, Thomas W. Feeley and Henry M. Kuerer
Purpose. Value in healthcare—i.e., patient-centered outcomes achieved per healthcare dollar spent—can define quality and unify performance improvement goals with health outcomes of importance to patients across the entire cycle of care. We describe the process... View Details
Keywords: Health Disorders; Value; Health Care and Treatment; Performance Improvement; Health Industry
Oluwadamilola, Fayanju M., Tinisha L. Mayo, Tracy E. Spinks, Seohyun Lee, Carlos H. Barcenas, Benjamin D. Smith, Sharon H. Giordano, Rosa F. Hwang, Richard A. Ehlers, Jesse C. Selber, Ronald Walters, Debu Tripathy, Kelly K. Hunt, Thomas A. Buchholz, Thomas W. Feeley, and Henry M. Kuerer. "Value-Based Breast Cancer Care: A Multidisciplinary Approach for Defining Patient-Centered Outcomes." Annals of Surgical Oncology 23, no. 8 (August 2016). (Published online early, March 15, 2016.)
- January 2005 (Revised March 2006)
- Case
Molecular Insight Pharmaceuticals, Inc.
By: Richard G. Hamermesh and Edwin W. Parkinson III
Molecular Insight has developed a novel biopharmaceutical to detect heart attacks. The company's unique approach to intellectual property protection uses the Hatch Waxman Act and the Orphan Drug Act. The company is struggling to raise $7 million in Series B financing.... View Details
Keywords: Intellectual Property; Health Care and Treatment; Pharmaceutical Industry; Health Industry
Hamermesh, Richard G., and Edwin W. Parkinson III. "Molecular Insight Pharmaceuticals, Inc." Harvard Business School Case 805-067, January 2005. (Revised March 2006.)
- January 2023
- Case
Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery
By: Regina Herzlinger and Brian Walker
What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful... View Details
Keywords: Product Development; Leadership; Health Testing and Trials; Research and Development; Risk and Uncertainty; Financial Condition; Partners and Partnerships; Pharmaceutical Industry
Herzlinger, Regina, and Brian Walker. "Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery." Harvard Business School Case 323-045, January 2023.
- 08 Jun 2020
- News
Tenants and Investors Will Be Looking for Healthy Buildings
- 26 Feb 2019
- First Look
New Research and Ideas, February 26, 2019
(Reg FD), which prohibits public firms from disclosing material information to certain parties but not others. Nevertheless, managers have continued to meet privately with select investors, possibly sharing information in violation of Reg... View Details
Keywords: Dina Gerdeman
- March 2014 (Revised February 2015)
- Case
Loki Capital Management
By: Joseph B. Fuller, Shikhar Ghosh and Matthew Preble
In December 2013, Michael Kane was preparing to launch his start-up's first hedge fund. While pleased with the development of the business, he wanted to address a few lingering issues before going any further. He debated whether or not to fire the company's chief... View Details
- Web
Employment Data
Starting own business 13% Company sponsored or already employed 3% Other 1% Postponing job search 0% Continuing education 0% No Data Available Median Base Salary $175,000 Median Signing Bonus $30,000 53% Receiving Median Variable Bonus... View Details
- 12 May 2020
- News
Coronavirus and the future of the workplace: 8 trends to watch
- June 2023
- Case
Verve Therapeutics: Taking DNA Editing to Heart
By: Shikhar Ghosh and Shweta Bagai
Verve Therapeutics, a public biotech company based in Boston, created a novel approach to addressing cardiovascular disease (CVD) - a leading cause of deaths globally. The company's approach was a single shot treatment to permanently lower cholesterol, thus reducing... View Details
Keywords: AI; Genetic Engineering; Medicine; Health Care and Treatment; Genetics; Innovation Strategy; Business and Stakeholder Relations; Medical Specialties; Innovation and Invention; Entrepreneurship; Biotechnology Industry
Ghosh, Shikhar, and Shweta Bagai. "Verve Therapeutics: Taking DNA Editing to Heart." Harvard Business School Case 823-113, June 2023.
- 10 Oct 2018
- Blog Post
6 Lessons Learned from a Summer of Entrepreneurship
As an unknown liquid dripped down my head and onto my face, I tried to keep my composure and continue our customer interview in Central Park. Melissa, my co-founder, helped me wipe my face as I wrapped up the interview. Our first day... View Details
Keywords: Entrepreneurship
- Research Summary
AIDS in Africa: Life, Death and Property Rights
By: Debora L. Spar
In the final years of the twentieth century, the world was hit by a plague of epidemic proportions--the plague of AIDS, a life-threatening disease that remained stubbornly immune to any cure or vaccine. In the developed nations of the West, AIDS was slowly brought... View Details
- 29 Jan 2019
- First Look
New Research and Ideas, January 29, 2019
David Grabowski, and David Cutler Abstract— Medicare’s Hospital Readmissions Reduction Program (HRRP) has been credited with lowering risk-adjusted readmission rates for targeted conditions at general acute care hospitals. However, these... View Details
Keywords: Dina Gerdeman
- 04 Dec 2017
- News
The CVS-Aetna Gamble: a Health-Care Giant Not Built Around Doctors
Nitin Nohria
Nitin Nohria served as the tenth dean of Harvard Business School from 2010-2020. He previously served as co-chair of the Leadership Initiative, Senior Associate Dean of Faculty Development, and Head of the Organizational Behavior unit.
As Dean, building on... View Details
- 30 Oct 2017
- News
Could a CVS-Aetna deal actually benefit consumers?
- 02 Jan 2024
- Research & Ideas
10 Trends to Watch in 2024
The lightning-fast ascent of generative AI isn’t the only sea change on the horizon for businesses in the new year. The global economy is in flux as war, climate change, trade issues, and infrastructure problems demand attention. Many companies continue to struggle to... View Details
Keywords: by Rachel Layne
- Web
Faculty & Advisors | MBA
Technology Chris leads MPM Capital’s public market investing as portfolio manager for BioImpact Equities (formerly known as Burrage Capital) and the Oncology Impact Funds. Previously, Chris was a health care analyst at Fidelity... View Details
- 14 Feb 2021
- Blog Post
Celebrating Love @ HBS in 2021
Love at HBS is an annual celebration of the diverse expressions of love that exist on our campus and in the world around us. Even with the unique challenges presented by the COVID-19 pandemic, love has endured, and our students have View Details